The FDA clearance allows Edesa to expand an ongoing placebo-controlled study of the CXCL10 antibody EB06 to US sites, with topline data expected in the fourth quarter of 2027.
|Videos|August 27, 2020
The role of antioxidants in vitiligo treatment
Author(s)Jessica Barry
Antioxidants can be a valuable part of your vitiligo therapeutic armamentarium, says expert Seemal R. Desai, M.D., FAAD.
Advertisement
View the video below to discover how Dr. Desai uses antioxidants to treat vitiligo, a topic he discussed at the AAD Virtual Meeting Experience (VMX) in June.
More videos with Dr. Desai:
Talk to your vitiligo patients about their treatment goals How to classify disease activity in vitiligo patients Best practices for unstable vitiligo
Stay tuned: What’s new in vitiligo treatment? Dr. Desai offers his insight in our upcoming video.
For more about AAD VMX,
Reference
Desai S. What's New in Vitiligo. Therapeutic Hotline. AAD VMX 2020; June 12, 2020.
Advertisement
Related to this article
Dermatology clinicians at a Case-Based Roundtable in Austin, Texas, discussed real-world strategies for sequencing topical therapy, phototherapy, and ruxolitinib cream across pediatric and adult vitiligo cases.
In TRANQUILLO 2, 21.86% of patients taking ritlecitinib 100 mg achieved F-VASI75 at week 52 vs 2.40% with placebo, according to data presented at EADV 2026.
The novel oral helicase-primase inhibitor demonstrated significantly higher rates of complete lesion healing compared with investigator’s choice treatment in the phase 3 PRIOH-1 trial.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
Galderma has agreed to acquire ZO Skin Health for $1.5 billion, adding the physician-dispensed skincare brand to a portfolio that already includes Cetaphil and Alastin.
New dermatology research explores hidden steroids in OTC products, infant eczema, melanoma prevention, cutaneous lymphoma, and pediatric AD.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Pritelivir for Refractory Mucocutaneous HSV in Immunocompromised Adults
2
GLP-1 Agonists Address Metabolic Risk in Psoriatic Disease
3
EB06 Phase 2 Vitiligo Study Receives FDA IND Clearance
4
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
5